

OIR  
AUG 12 2002  
COPY OF PAPERS  
ORIGINALLY FILED

GP/3736

CERTIFICATE OF MAILING

I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 7/12 day of August, 2002.

Typed or Printed name of person signing this certificate:  
Wendy A. Frick

Signed: Wendy A. Frick

24024  
PATENT TRADEMARK OFFICE

AUG 26 2002

RECEIVED

PATENT

D#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Hazen, et al. )  
Serial No.: 10/039,753 )  
Filed: January 2, 2002 )  
For: MYELOPEROXIDASE, A RISK )  
INDICATOR FOR CARDIOVASCULAR )  
DISEASE )

Examiner: Not yet assigned

Art Unit: 3736

Attorney Docket No.: 26473/041 TECHNOLOGY CENTER R3700

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
Sir:

Transmitted herewith are the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449;
3. 8 References; and
4. A Return Receipt Postcard.


It is believed that no further fee is required relating to the filing of this Supplemental Information Disclosure Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: August 7, 2002

By: Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416

RECEIVED  
AUG 14 2002  
TECHNOLOGY CENTER R3700

COPY OF PAPERS  
ORIGINALLY FILED

Page 1 of 1

Subst. Form PTO-1449

Atty. Docket No.: 26473/04177

Serial No.: 10/039,753

APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT

Applicant: Hazen, et al.

Filing Date: January 2, 2002

RECEIVED  
AUG 14 2002  
TECHNOLOGY CENTER A3700

Group: 3736

TECH CENTER A3700  
1600/2900RECEIVED  
AUG 26 2002

## U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						
	AC						
	AD						

## FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AE						
	AF						
	AG						
	AH						
	AI						

## OTHER PRIOR ART

	AJ	"Myeloperoxidase Deficiency" by Nauseef, <i>Hematology, Oncology Clinics of North America</i> , Vol. 2, No.1, March 1988, pp. 135-158.
	AK	"Primary Inherited Defects in Neutrophil Function: Etiology and Treatment" by Malech, et al., <i>Seminars in Hematology</i> , Vol. 34, No. 4, October, 1997, pp. 279-290.
	AL	"Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall" by Heinecke, et al., <i>FASEB J.</i> , 13, 1113-1120 (1999).
	AM	"Myeloperoxidase-Generated Oxidants and Atherosclerosis" by Podrez, et al., <i>Free Radical Biology &amp; Medicine</i> , Vol. 28, No. 12, pp. 1717-1725, January, 2000.
	AN	"Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerosis Lesions" by Daugherty, et al., <i>J. Clin. Invest.</i> , Vol. 94, July 1994, 437-444.
	AO	"3-Chlorotyrosine, a Specific Marker of Myeloperoxidase-catalyzed Oxidation, Is Markedly Elevated in Low Density Lipoprotein Isolated from Human Atherosclerosis Intima" by Hazen, et al., <i>J. Clin. Invest.</i> , Vol. 99, No. 9, May, 1997, 2075-2081.
	AP	"Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino acid-derived aldehyde generated by myeloperoxidase, are present in hun fatty streaks, intermediate lesions and advanced atherosclerosis lesions' by Hazen, et al., <i>Biochem J.</i> (2000) 352, 693-699.
	AQ	"p-Hydroxypheylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerosis Intima" by Heller, et al., <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 14, April 7, 2000, pp. 9957-9962.
	AR	

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.